The International Workshop on Non-Hodgkin Lymphoma

The Virtual iwNHL 2020 meeting will be held online on 11th to 12th September. The workshop will highlight efforts to understand the biology of different NHL subtypes to further refine therapeutic strategies. Some of the world’s leading clinical researchers in NHL will share their perspectives on how to place this evolving understanding in a clinical context and thereby optimize clinical care.

Please note, the iwNHL virtual workshop is for treating hematologists, researchers, nurses, and allied medical professionals only.

iwNHL Programme

Friday: September 11, 2020

10:00 (EST)

Introduction & Virtual Meeting Objectives
John Gribben

10:05-10:55

Session I: Hodgkin’s Lymphoma

Chairs: Peter Johnson & Pier Luigi Zinzani 

  • Early-stage unfavorable cHL; Peter Borchmann
  • KEYNOTE 204; Pier Luigi Zinzani
  • Hodgkin’s Lymphoma in the era of targeted therapy; Peter Johnson


Roundtable Discussion

10:55-11:45

Session II: Immunotherapy/Microenvironment

Chairs: David Maloney & Stephen Ansell

  • Crosstalk between lymphocytes and their microenvironment; Patricia Pérez Galán
  • PRAME expression and the tumor microenvironment; David Scott
  • CBT in specific lymphoma subtypes; Stephen Ansell


Roundtable Discussion

11:45-12:35

Session III: Novel Therapies Part I

Chairs: Laurie Sehn & Franck Morschhauser

  • Novel ADCs; Laurie Sehn
  • CD20 / CD3 bispecific antibodies: How to choose?; Martin Hutchings
  • Oral PI3K delta (δ) inhibitors in lymphoma; Jennifer Brown


Roundtable Discussion

12:35-15:00

Roundup of Day 1:
John Gribben, Stephen Ansell, Laurie Sehn & Franck Morschhauser

Saturday: September 12, 2020

10:00-10:55

Session IV: Novel Therapies Part II

  • Novel BTK inhibitors: how to choose?; Tom Witzig
  • SINE inhibitors: Selinexor; Sundar Jagannath
  • Tafasitamab (MOR208) in DLBCL; Gilles Salles


Roundtable Discussion

10:55-11:45

Session V: T-cell Therapies for Lymphoma

Chairs: Cath Bollard & Jeremy Abramson 

  • CD19-CAR-T cells; Jeremy Abramson
  • CD30, CD5 and/or 7 CAR-T cells; Cath Bollard
  • T cell-engaging therapies – BiTEs and beyond; Ralf C. Bargou


Roundtable Discussion

11:45-12:00

Final Virtual Meeting Summary & Conclusions
iwNHL Scientific Committee

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter